SKYE — Skye Bioscience Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual balance sheet for Skye Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash
Cash and Equivalents
Cash and Short Term Investments	2.47	8.98	1.24	1.43	70.4
Net Total Receivables	—	—	—	0.032	0.005
Prepaid Expenses
Total Other Current Assets
Total Current Assets	2.66	9.61	8.94	11.7	70.8
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	0.007	0.235	0.159	0.281	1.88
Other Long Term Assets
Total Assets	2.67	9.86	9.11	11.9	72.8
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	0.787	3.91	12.1	13.9	4.34
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	2.22	3.99	12.1	14.1	4.61
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Total Equity	0.451	5.86	-3.01	-2.13	68.2
Total Liabilities & Shareholders' Equity	2.67	9.86	9.11	11.9	72.8
Total Common Shares Outstanding
Total Preferred Shares Outstanding